IL37 and psoriasis: Advancements in our understanding of the pathogenesis of psoriasis have facilitated the identification of numerous potential therapeutic targets, including anti-tumor necrosis factor (TNF)-α, anti-interleukin (IL)-17, anti-IL-12/23, and anti-IL-23 therapies [21,22].